The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells
Abstract
Nanoparticles represent useful drug delivery systems for the specific transport of drugs to tumour cells. In the present study biodegradable nanoparticles based on gelatin and human serum albumin (HSA) were developed. The surface of the nanoparticles was modified by covalent attachment of the biotin-binding protein NeutrAvidin enabling the binding of biotinylated drug targeting ligands by avidin-biotin-complex formation. Using the HER2 receptor specific antibody trastuzumab (Herceptin) conjugated to the surface of these nanoparticles, a specific targeting to HER2-overexpressing cells could be shown. Attachment of the antibody-conjugated nanoparticles to the surface of HER2-overexpressing cells was time and dose dependent. Confocal laser scanning microscopy demonstrated an effective internalisation of the nanoparticles by HER2-overexpressing cells via receptor-mediated endocytosis. The results indicate that nanoparticles conjugated with an antibody against a specific tumour antigen holds promise, as selective drug delivery systems for the treatment of tumours expressing a specific tumour antigen. To our knowledge, this is the first study that demonstrates the effective and specific targeting of protein-based nanoparticles as drug delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Cited by
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy
Lohcharoenkal, W., Wang, L., Chen, Y. C., & Rojanasakul, Y. (2014) · BioMed Research International · doi:10.1155/2014/180549 · Cited by 655
Metadata
- Authors
- Wartlick, H., Michaelis, K., Balthasar, S., Strebhardt, K., Kreuter, J., & Langer, K.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2004-08
- Volume
- 12
- Issue
- 7
- Pages
- 461-471
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2025017345
- Cited by
- 211
- References
- 1
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells. https://app.cochat.ai/papers/10.1080/10611860400010697
- The paper
- Wartlick, H., Michaelis, K., Balthasar, S., Strebhardt, K., Kreuter, J., & Langer, K. (2004). Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells. Journal of Drug Targeting. https://doi.org/10.1080/10611860400010697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.